Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 15/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27629323 | 0.78 | MEN1 (0.58) | CYP19A1KDM4EMAPK1L3MBTL1MEN1 | |
| SCHEMBL23913862 | 0.78 | MAPK1 (0.53) | CYP19A1CYP11B1CYP11B2KDM4EMAPK1 | |
| SCHEMBL4833617 | 0.77 | MEN1 (0.53) | CYP19A1CYP11B1CYP11B2KDM4EMAPK1 | |
| SCHEMBL29788840 | 0.77 | ALDH1A1 (0.65) | CYP19A1CYP11B1CYP11B2KDM4EMAPK1 | |
| SCHEMBL10053477 | 0.77 | MEN1 (0.53) | CYP19A1CYP11B1CYP11B2KDM4EMAPK1 | |
| SCHEMBL708243 | 0.77 | KDM4E (0.51) | CYP19A1CYP11B1CYP11B2KDM4EMAPK1 | |
| SCHEMBL9156641 | 0.76 | CYP19A1 (1.00) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL2532477 | 0.76 | CYP19A1 (0.55) | CYP19A1CYP11B1CYP11B2KDM4EMAPK1 | |
| SCHEMBL2286797 | 0.74 | CYP11B1 (0.64) | CYP19A1CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL9978689 | 0.74 | CYP19A1 (0.53) | CYP19A1CYP11B1CYP11B2KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0408509-B1 | Substituted benzonitriles | CIBA GEIGY AG (CH) | 1996-03-06 | — | — | EP | claimed |
| US-5073574-A | TETRAZOLYL SUBSTITUTED BENZONITRILES AND ANTI-TUMOR USE THEREOF | CIBA-GEIGY CORPORATION (US) | 1991-12-17 | — | — | US | claimed |
| EP-0408509-A2 | Substituted benzonitriles | CIBA-GEIGY AG (CH) | 1991-01-16 | — | — | EP | claimed |
| US-11845767-B2 | Arginase inhibitors | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2023-12-19 | — | — | US | disclosed |
| US-20220227791-A1 | NOVEL ARGINASE INHIBITORS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2022-07-21 | — | — | US | disclosed |
| CN-100384418-C | Isoxazolopyridinones and use thereof in the treatment of parkinson's disease | NOVARTIS AG (CH) | 2008-04-30 | — | — | CN | disclosed |
| EP-1418912-B1 | ISOXAZOLOPYRIDINONES | NOVARTIS AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-7087756-B2 | Isoxazolopyridinones | NOVARTIS AG (CH) | 2006-08-08 | — | — | US | disclosed |
| CN-1635889-A | Isoxazolopyridinones and their use in the treatment of parkinson's disease | NOVARTIS AG (CH) | 2005-07-06 | — | — | CN | disclosed |
| US-20040248893-A1 | Isoxazolopyridinones | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1418912-A2 | ISOXAZOLOPYRIDINONES | Novartis AG (CH) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003015780-A2 | ISOXAZOLOPYRIDINONES AND USE THEREOF IN THE TREATMENT OF PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2003-02-27 | — | — | WO | disclosed |
| EP-0408509-B1 | Substituted benzonitriles | CIBA GEIGY AG (CH) | 1996-03-06 | — | — | EP | disclosed |
| US-5073574-A | TETRAZOLYL SUBSTITUTED BENZONITRILES AND ANTI-TUMOR USE THEREOF | CIBA-GEIGY CORPORATION (US) | 1991-12-17 | — | — | US | disclosed |
| EP-0408509-A2 | Substituted benzonitriles | CIBA-GEIGY AG (CH) | 1991-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248893-A1 | Isoxazolopyridinones | XDH, NPY1R, TBXA2R | CYP19A1 168/4885CYP11B1 41/4885CYP11B2 40/4885 |
| US-20220227791-A1 | NOVEL ARGINASE INHIBITORS | ARG1, ARG2, ARGLU1 | CYP19A1 464/4885CYP11B1 157/4885CYP11B2 232/4885 |
| US-11845767-B2 | Arginase inhibitors | ARG1, ARG2, ARGLU1 | CYP19A1 425/4885CYP11B1 117/4885CYP11B2 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.